Voglibose

 Voglibose (INN and USAN, trade name Voglib, marketed by Mascot Health Series) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus.[1] Voglibose delays the absorption of glucose thereby reducing the risk of macrovascular complications. Voglibose is a research product of Takeda Pharmaceutical Company, Japan's largest pharmaceutical company. Voglibose was first launched in 1994, under the trade name BASEN, to improve postprandial hyperglycemia in diabetes mellitus.[2]

Voglibose
Voglibose structure.svg
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
  • A10BF03 (WHO)
Identifiers
IUPAC name
  • (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)-1-(hydroxymethyl)cyclohexane-1,2,3,4-tetraol
CAS Number
  • 83480-29-9 check
PubChem CID
  • 444020
DrugBank
  • DB04878 check
ChemSpider
  • 392046 check
UNII
  • S77P977AG8
KEGG
  • D01665 check
ChEMBL
  • ChEMBL476960 check
CompTox Dashboard (EPA)
  • DTXSID2021442 Edit this at Wikidata
Chemical and physical data
FormulaC10H21NO7
Molar mass267.278 g·mol−1
3D model (JSmol)
  • Interactive image
SMILES
  • OC[C@@]1(O)C[C@H](NC(CO)CO)[C@H](O)[C@@H](O)[C@@H]1O
InChI
  • InChI=1S/C10H21NO7/c12-2-5(3-13)11-6-1-10(18,4-14)9(17)8(16)7(6)15/h5-9,11-18H,1-4H2/t6-,7-,8+,9-,10-/m0/s1 check
  • Key:FZNCGRZWXLXZSZ-CIQUZCHMSA-N check
  (verify)

Postprandial hyperglycemia (PPHG) is primarily due to first phase insulin secretion. Alpha glucosidase inhibitors delay glucose absorption at the intestine level and thereby prevent sudden surge of glucose after a meal.

There are three drugs which belong to this class, acarbose, miglitol and voglibose, of which voglibose is the newest.

This article uses material from the Wikipedia article
 Metasyntactic variable, which is released under the 
Creative Commons
Attribution-ShareAlike 3.0 Unported License.